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Objectives. This study evaluated the relative merits of the most
frequently used techniques for predicting improvement in re-
gional contractile function after coronary revascularization in
patients with left ventricular dysfunction due to chronic coronary
artery disease.
Background. Several techniques have been proposed for pre-
dicting improvement in regional contractile function after
revascularization, including thallium-201 (Tl-201) stress–
redistribution–reinjection, Tl-201 rest–redistribution, fluorine-18
fluorodeoxyglucose with positron emission tomography, technetium-
99m sestamibi imaging and low dose dobutamine echocardiogra-
phy (LDDE).
Methods. A systematic review of all reports on prediction of
functional recovery after revascularization in patients with
chronic coronary artery disease (published between 1980 and
March 1997) revealed 37 with sufficient details for calculating the
sensitivity and specificity of each imaging modality. From the
pooled data, 95% and 99% confidence intervals were also calcu-
lated.
Results. Sensitivity for predicting regional functional recovery
after revascularization was high for all techniques. The specificity
of both Tl-201 protocols was significantly lower (p < 0.05) and
LDDE significantly higher (p < 0.01) than that of the other
techniques.
Conclusions. Pooled analysis of 37 studies showed that al-
though all techniques accurately identify segments with improved
contractile function after revascularization, the Tl-201 protocols
may overestimate functional recovery. The evidence available thus
far indicates that LDDE appears to have the highest predictive
accuracy.
(J Am Coll Cardiol 1997;30:1451–60)
©1997 by the American College of Cardiology
The awareness that even severely dyssynergic myocardium in
patients with chronic coronary artery disease (CAD) may show
an improvement in functional state after revascularization
(1,2) has resulted in a search for the optimal diagnostic
approach to identify areas with recoverable dysfunction (3).
Reversal of myocardial dysfunction is particularly relevant in
patients with depressed ventricular function because surgical
revascularization improves long-term survival in such patients
(4,5). However, surgical intervention is associated with a
higher risk for perioperative complications and mortality in the
same patient subset (6). Thus, it becomes critical to identify
and select those patients who may benefit from a revascular-
ization procedure. The morphologic characterization of the
dysfunctional myocardium (7–9) has led to further insights into
the mechanisms that determine the presence or absence of
functional recovery after revascularization. Contractile dys-
function may be caused by necrotic myocardium or by jeopar-
dized but viable myocardium. If the dysfunction is due to
fibrosis, no recovery can be expected after revascularization; if
the dysfunction is due to jeopardized but viable myocardium,
recovery can occur in some patients (9–11). Although the exact
pathophysiology of dysfunctional but viable myocardium re-
mains controversial (1,2,11,12), the potential for functional
recovery has clinical relevance. Indeed, whatever the exact
mechanism of reversible dysfunction, revascularization is re-
quired for functional recovery.
Several techniques have been developed to identify dys-
functional but viable myocardium, including positron emission
tomography (PET) with fluorine-18 fluorodeoxyglucose (F-18
FDG), thallium (Tl)-201 stress–redistribution–reinjection, Tl-
201 rest–redistribution, single-photon emission computed to-
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mography (SPECT) with technetium-99m sestamibi (Tc-99m
MIBI) and low dose dobutamine echocardiography (LDDE).
However, the relative merits of the various techniques in the
prediction of functional recovery after revascularization re-
main a matter of debate. To provide more insight into this
issue, we performed a pooled analysis of the presently available
data supporting the use of the aforementioned imaging mo-
dalities for the prediction of functional recovery.
Methods
Review of published reports. The objective of the current
analysis was to evaluate the available published reports on the
relative merits of F-18 FDG PET, Tl-201 stress–redistribution–
reinjection, Tl-201 rest–redistribution, Tc-99m MIBI and
LDDE for prediction of recovery of regional left ventricular
(LV) function after revascularization. The studies were iden-
tified by means of several combined search strategies: 1) A
search of the MEDLINE data base (January 1980 to Decem-
ber 1996) was conducted using the following key words: Tl-201
rest–redistribution, Tl-201 reinjection, Tc-99m MIBI, dobut-
amine echocardiography, F-18 FDG and myocardial viability.
2) A manual search of eight cardiology and nuclear medicine
journals (American Heart Journal, American Journal of Cardi-
ology, British Heart Journal/Heart, Circulation, European
Heart Journal, European Journal of Nuclear Medicine, Journal of
the American College of Cardiology and Journal of Nuclear
Medicine) from January 1980 to March 1997 was carried out. 3)
The reference lists of the reports obtained through these
searches were screened for additional articles that might have
been missed. 4) The list of articles was then reviewed by the
co-investigators, all of whom are active in the field. Only
articles in English were considered, and reviews or abstracts
were disregarded.
Inclusion criteria. For inclusion in the analysis, the follow-
ing criteria had to be met: 1) the study was prospective and
evaluated one or more of the aforementioned five techniques;
2) the technique was tested for predictive accuracy versus
functional outcome after revascularization, assessed during
follow-up; 3) the study evaluated only patients with chronic,
stable LV dysfunction; 4) the study contained sufficient details
so that the sensitivity and specificity for predicting improve-
ment in regional LV function could be calculated. In cases
where these details were not readily available, a co-investigator
of that particular study was approached to supply the relevant
information.
Exclusion criteria. Exclusion criteria were 1) studies as-
sessing viability with any of the techniques but without func-
tional follow-up after revascularization; and 2) studies in
patients with acute ischemic syndromes (including viability
assessment within 1 month after infarction).
From the pooled data, weighted sensitivities (number of
viable segments divided by the number of segments with
improved function after revascularization) and specificities
(number of nonviable segments divided by the number of
segments without improved function after revascularization)
were calculated. The 95% confidence intervals (CIs) of the
weighted sensitivities and specificities were also calculated
from the following formula: p 6 1.96 3 ={p 3 (1 2 p)/n},
where p 5 the number of viable segments divided by the number
of segments with improved function after revascularization or the
number of nonviable segments divided by the number of seg-
ments without improvement after revascularization; and n 5 the
total population. For example, if sensitivity is 80% and the total
number of segments is 100, the 95% CI is calculated as follows:
0.80 6 1.96 3 ={0.80 3 (1 2 80)/100}. Similarly, the 99% CIs
were calculated using the following formula: p 6 2.575 3
={p 3 (1 2 p)/n}. The 95% and 99% CIs were calculated for
each technique, and the individual intervals were compared.
Differences between techniques were considered signifi-
cant at the 0.05 level when 95% CI did not overlap and
significant at the 0.01 level when 99% CIs did not overlap.
The majority of the studies in patients undergoing revascu-
larization concentrated on changes in regional contraction. For
the individual patient, improvement in global LV function is
the most clinically relevant factor. When available, these data
are included and discussed for each technique anecdotally.
Because of the limited data available for prediction of global
LV improvement and their descriptive nature, it was not
possible to assess pooled sensitivity/specificity figures.
Results
A total of 396 reports were identified by means of the
different search strategies, with only 37 fulfilling the inclusion
criteria. The reasons for exclusion were: 1) absence of revas-
cularization (275 reports); 2) experimental studies (animal
models, 43 reports); 3) revascularization in patients with acute
ischemic syndromes (21 reports); 4) insufficient information
for calculation of sensitivity and specificity on a segmental basis
(3 reports); and 5) study design not allowing calculation of
sensitivity and specificity (17 studies in which the preoperative
viability test results were given for patients with and without
functional recovery as determined postoperatively, emphasiz-
ing the pathophysiologic differences between patients with and
without viable myocardium; these data do not permit calcula-
tion of sensitivity and specificity). The results of the pooled
Abbreviations and Acronyms
CAD 5 coronary artery disease
CI 5 confidence interval
F-18 FDG 5 fluorine-18 fluorodeoxyglucose
LDDE 5 low dose dobutamine echocardiography
(echocardiographic)
LV 5 left ventricular
LVEF 5 left ventricular ejection fraction
PET 5 positron emission tomography (tomographic)
SPECT 5 single-photon emission computed tomography
(tomographic)
Tc-99m MIBI 5 technetium-99m sestamibi
Tl-201 5 thallium-201
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analysis of the 37 remaining studies are discussed in detail for
each technique.
Metabolic imaging with F-18 FDG and PET. Since the
original observation by Marshall et al. (13) in 1981, consider-
able evidence has accumulated to show that F-18 FDG in
combination with PET can detect viable myocardium (14,15).
F-18 FDG is a glucose analogue that traces exogenous glucose
uptake by the myocardium. Viable myocardium is character-
ized by preserved F-18 FDG uptake.
Diagnostic accuracy for prediction of regional improvement.
Many studies have used F-18 FDG PET to predict functional
recovery in patients undergoing revascularization (16–27). The
results from these studies are summarized in Table 1. Reanal-
ysis of the original data (obtained in 332 patients) showed that
the sensitivity ranged from 71% to 100%, with a weighted
mean of 88%. Specificity ranged from 38% to 91%, with a
weighted mean of 73%.
Diagnostic accuracy for prediction of global improvement.
Revascularization in patients with preserved F-18 FDG uptake
was shown to result in improved LV ejection fraction (LVEF)
(9–11,17,25,26,28–32). In the study by Tillisch et al. (26),
LVEF improved from 30 6 11% to 45 6 14% (mean 6 SD) in
the patients with two or more viable, dysfunctional segments
on F-18 FDG PET, whereas LVEF did not improve in the
patients with one or less viable, dysfunctional segment. Com-
parable findings have been recently reported (10,28,29).
Areas of ongoing research. On the basis of F-18 FDG PET
results, several reports have recently evaluated the feasibility of
cardiac F-18 FDG imaging with SPECT cameras equipped
with 511-keV collimators to allow F-18 FDG imaging in
centers without PET facilities (33,34).
Tl-201 scintigraphy. The initial uptake of Tl-201 by myo-
cytes is mainly determined by regional perfusion, whereas the
integrity of the cell membrane is predominantly important for
delayed imaging of tracer retention. Although different Tl-201
protocols have been described (3), both Tl-201 stress–
redistribution–reinjection and Tl-201 rest–redistribution are
currently used for prediction of functional recovery.
Tl-201 stress–redistribution–reinjection imaging. Diagnos-
tic accuracy for prediction of regional improvement. Several
studies have shown (35–37) that reinjection of 1 mCi of Tl-201
after 3- to 4-h redistribution imaging detects viability in 31% to
49% of segments deemed irreversibly damaged because they
showed a fixed defect on conventional stress–redistribution
Tl-201 imaging. Bonow et al. (38) showed concordance be-
tween Tl-201 stress–redistribution–reinjection and F-18 FDG
PET for the presence or absence of viable myocardium in 88%
of segments; however, postrevascularization results were not
reported.
It also appears that semiquantitation of Tl-201 activity is
important. The majority of mild to moderate (Tl-201 activity
$50% of normal) fixed defects on redistribution (38) and
reinjection images (39) are viable on F-18 FDG PET.
Seven studies (27,34,35,37,40–42) have evaluated the diag-
nostic accuracy of Tl-201 stress–redistribution–reinjection for
assessing improvement in regional function after revascular-
ization. Reanalysis of the available data revealed that Tl-201
stress–redistribution–reinjection imaging has a high sensitivity
(average 86%) but a relatively low specificity (average 47%)
(Table 2). These results suggest an overestimation of potential
recovery by Tl-201 stress–redistribution–reinjection imaging.
Table 1. Sensitivity and Specificity of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Detection of Improved Regional
Contractile Function After Revascularization
Study (ref no.)
No. of
Pts
Male
(%)
Mean Age
(yr)
Mean LVEF
(SD) (%)
Pts With
MVD
(%)
Pts With
Prev MI (%)
Segs With
Recovery
(%)
Technique
Assessing
RWM After
Revasc
Sens (%)
(no. of segs)
Spec (%)
(no. of segs)
Marwick et al. (16) 16 88 NA NA 44 100 41 Echo 71 (25/35) 76 (38/50)
Gerber et al. (17) 39 87 60 33 (610) 85 59 62 Echo 75 (18/24) 67 (10/15)
Tamaki et al. (18) 22 91 57 NA NA 77 50 RNV 78 (18/23) 78 (18/23)
Gropler et al. (19) 34 76 60 NA 76 62 40 Echo/RNV 83 (38/46) 50 (35/70)
Maes et al. (20) 23 NA NA 41 (613) NA NA 52 RNV 83 (10/12) 91 (10/11)
Tamaki et al. (21) 43 95 58 41 (NA) NA 100 39 CV/RNV 88 (45/51) 82 (65/79)
Knuuti et al. (22) 48 96 54 53 (611) 85 100 30 Echo 92 (23/25) 85 (50/59)
Baer et al. (23) 42 90 59 40 (613) 74 100 62 Echo 92 (24/26) 88 (14/16)
Lucignani et al. (24) 14 86 61 38 (65) 93 NA 74 RNV 93 (37/40) 86 (12/14)
Carrel et al. (25) 23 91 56 34 (614) NA 100 74 Echo 94 (16/17) 50 (3/6)
Tillisch et al. (26) 17 94 NA 32 (614) NA 94 55 CV/RNV 95 (35/37) 80 (24/30)
Tamaki et al. (27) 11 NA NA NA NA NA 71 RNV 100 (40/40) 38 (6/16)
Average 28 90 58 40 78 88 51
Weighted mean 88 (329/376) 73 (285/390)
CV 5 contrast ventriculography; Echo 5 echocardiography; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction; MVD 5 multivessel disease;
NA 5 not available; Prev 5 previous; Pts 5 patients; ref 5 reference; Revasc 5 revascularization; RNV 5 radionuclide ventriculography; RWM 5 regional wall
motion; Segs 5 segments; Sens 5 sensitivity; Spec 5 specificity.
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Diagnostic accuracy for prediction of global improvement.
Bax et al. (34) evaluated 17 patients with Tl-201 reinjection
imaging to assess improvement of global function after revas-
cularization. Tl-201 reinjection identified five of six patients
who demonstrated improvement in LVEF of at least 5%. Of
the 11 patients with no improvement in global function, Tl-201
reinjection identified nonviable myocardium in six. Vanover-
schelde et al. (42) recently reported a sensitivity of 72% and a
specificity of 73% for Tl-201 reinjection imaging in predicting
improved global LV function.
Tl-201 rest–redistribution imaging. Diagnostic accuracy for
prediction of regional improvement. Whereas Tl-201 stress–
redistribution–reinjection scintigraphy provides information
on both exercise-induced ischemia and viability, Tl-201 rest–
redistribution provides information on viability only. Two
studies (43,44) compared Tl-201 stress–redistribution–
reinjection with Tl-201 rest–redistribution imaging and showed
a concordance between the two techniques of 80%, at least
when defect reversibility was considered an indicator of viabil-
ity. When the severity of Tl-201 activity in irreversible defects
was considered, the concordance increased to 94% (43). In
addition, Dilsizian et al. (43) showed that F-18 FDG PET and
Tl-201 rest–redistribution imaging yielded comparable infor-
mation regarding viability when the Tl-201 rest–redistribution
studies were analyzed semiquantitatively.
Eight studies (45–52) evaluated the use of Tl-201 rest–
redistribution imaging to predict improvement of regional
contractility after revascularization. In these studies the aver-
age sensitivity and specificity were 90% and 54% (Table 3),
also suggesting some overestimation of recovery by Tl-201
rest–redistribution imaging.
Diagnostic accuracy for prediction of global improvement.
Iskandrian et al. (53) studied 26 patients and showed that
Tl-201 rest–redistribution identified 12 of 14 patients who
demonstrated improvement in LVEF of at least 5% after
revascularization. In contrast, Tl-201 rest–redistribution iden-
tified 8 of 12 patients with no improvement. Comparable
results were reported in other studies (45,48).
Tc-99m MIBI. Myocardial uptake of Tc-99m MIBI paral-
lels regional perfusion and provides adequate information for
Table 2. Sensitivity and Specificity of Thallium-201 Reinjection Imaging for Detection of Improved Regional Contractile Function
After Revascularization
Study (ref no.)
No. of
Pts
Male
(%)
Mean Age
(yr)
Mean LVEF
(SD) (%)
Pts With
MVD (%)
Pts With
Prev MI
(%)
Segs With
Recovery
Technique Assessing
RWM After Revasc
Sens (%)
(no. of segs)
Spec (%)
(no. of segs)
Vanoverschelde
et al. (42)
73 85 59 36 (612) 79 68 38 Echo/RNV 80 (213/267) 47 (198/425)
Ohtani et al. (37) 24 75 62 NA 100 58 61 RNV 89 (33/37) 50 (12/24)
Arnese et al. (40) 38 68 59 31 (NA) 92 100 22 Echo 89 (34/38) 48 (63/132)
Bax et al. (34) 17 82 57 36 (611) 100 100 29 Echo 93 (25/27) 43 (28/65)
Tamaki et al. (27) 11 NA NA NA NA NA 71 RNV 95 (38/40) 38 (6/16)
Dilsizian et al. (35) 20 88 58 NA 61 NA 57 RNV 95 (35/37) 80 (8/10)
Haque et al. (41) 26 81 55 43 (614) 56 88 77 Echo 100 (33/33) 40 (4/10)
Average 30 80 59 36 81 79 45
Weighted mean 86 (411/479) 47 (319/682)
Abbreviations as in Table 1.
Table 3. Sensitivity and Specificity of Thallium-201 Rest–Redistribution Imaging for Detection of Improved Regional Contractile Function
After Revascularization
Study (ref no.)
No. of
Pts
Male
(%)
Mean Age
(yr)
Mean LVEF
(SD) (%)
Pts With
MVD (%)
Pts With
Prev MI
(%)
Segs With
Recovery
Technique Assessing
RWM After Revasc
Sens (%)
(no. of segs)
Spec (%)
(no. of segs)
Mori et al. (45) 17 82 62 37 (67) 52 100 51 RNV 44 (11/25) 88 (23/26)
Marzullo et al. (46) 14 79 54 39 (67) 93 100 65 Echo 86 (42/49) 92 (24/26)
Udelson et al. (47) 18 72 67 34 (610) NA 100 37 Echo 88 (15/17) 83 (24/29)
Qureshi et al. (52) 34 NA 61 39 (614) 76 56 28 Echo 90 (38/42) 56 (59/106)
Ragosta et al. (48) 21 86 64 27 (65) 100 76 51 RNV 93 (81/89) 31 (27/87)
Alfieri et al. (49) 13 100 52 35 (68) NA NA 82 Echo 94 (92/98) 64 (14/22)
Charney et al. (50) 10 NA NA NA NA NA 61 Echo 95 (19/20) 85 (11/13)
Perrone-Filardi
et al. (51)
18 NA NA NA NA NA 69 Echo 100 (73/73) 22 (8/36)
Average 18 83 61 35 80 81 51
Weighted mean 90 (371/413) 54 (188/345)
Abbreviations as in Table 1.
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the detection of CAD (54). The uptake and retention of
Tc-99m MIBI is also dependent on cell membrane integrity
and mitochondrial function (membrane potential) (55–57) and
thus may reflect cellular viability. Many studies have compared
Tc-99m MIBI imaging with other scintigraphic modalities,
including Tl-201 stress–redistribution–reinjection (58,59), Tl-
201 rest (46,47,60,61), Tl-201 rest–redistribution (60,62–64)
and F-18 FDG PET (20,63,65–69). These concordance studies
were consistent in showing that Tc-99m MIBI was less accurate
in the detection of myocardial viability.
Diagnostic accuracy for prediction of regional improvement.
The results of studies that evaluated Tc-99m MIBI imaging
with regard to functional outcome after revascularization are
summarized in Table 4 (20,46,47,70–73). All studies reported a
high sensitivity, whereas specificity varied considerably from
35% to 86%. Recently, the administration of nitrates before
Tc-99m MIBI imaging has been described (74–76). Three
studies that have used this approach suggest an improved
specificity (Table 4).
Diagnostic accuracy for prediction of global improvement. At
present, no published data are available on the diagnostic
accuracy of Tc-99m MIBI imaging for predicting improvement
of global function.
Areas of ongoing research. Several approaches can poten-
tially improve the diagnostic accuracy of Tc-99m MIBI, includ-
ing stress–rest imaging (71), gated SPECT (71,77), semiquan-
titative analysis (47,59) and delayed imaging after tracer
administration (59).
LDDE. Echocardiography during the infusion of low dose
dobutamine (5 to 15 mg/kg body weight per min) has been
proposed as an alternative method for assessing myocardial
viability in patients with chronic ischemic heart disease (78).
The hallmark of viability is improved contraction of a dyssyn-
ergic segment after adrenergic stimulation. Several studies
have compared LDDE with other imaging modalities to assess
viability, including F-18 FDG PET (17,23,79), Tl-201 stress–
redistribution–reinjection (34,40 – 42,80,81), Tl-201 rest–
redistribution (46,49–52) and Tc-99m MIBI (46), showing
good agreement in most studies.
Diagnostic accuracy for prediction of regional improvement.
The available studies that have evaluated LDDE for detecting
functional recovery after revascularization in patients with
chronic CAD are summarized in Table 5 (17,23,34,40 –
42,46,49–52,79,82–86). The results indicate that LDDE ade-
quately detects recovery of contractile function after revascu-
larization, with a mean sensitivity of 84% and a mean
specificity of 81%. It is worth mentioning that all studies with
low dose dobutamine have used echocardiography, rather than
an independent technique, to assess improvement of regional
wall motion.
Diagnostic accuracy for prediction of global improvement.
Meluzin et al. (87) showed that LVEF increased from 38 6 5%
to 42 6 5% after revascularization in patients with contractile
reserve but did not improve in patients without contractile
reserve. Moreover, the improvement in LVEF was linearly
related to the number of segments with contractile reserve on
LDDE, indicating that the amount of jeopardized but viable
tissue determines the magnitude of improvement of LV func-
tion (87). Several studies (34,42,84) have now confirmed these
findings.
Table 4. Sensitivity and Specificity for Technetium-99m Sestamibi Scintigraphy With and Without Addition of Nitrates for Detection of
Functional Recovery After Revascularization
Study (ref no.)
No. of
Pts
Male
(%)
Mean Age
(yr)
Mean LVEF
(SD) (%)
Pts With
MVD (%)
Pts With
Prev MI
(%)
Segs With
Recovery
(%)
Technique Assessing
RWM After Revasc
Sens (%)
(no. of segs)
Spec (%)
(no. of segs)
Technetium-99m Sestamibi Scintigraphy Without Addition of Nitrates
Marzullo et al. (70) 22 86 57 44 (613) 91 100 56 Echo 73 (40/55) 54 (27/50)
Marzullo et al. (46) 14 79 54 39 (67) 93 100 65 Echo 75 (37/49) 84 (22/26)
Gonzalez et al. (71) 36 89 57 52 (615) 72 86 43 Echo 80 (30/39) 35 (18/51)
Marzullo et al. (72) 14 93 55 43 (69) 93 100 57 Echo 83 (35/42) 68 (21/31)
Maes et al. (20) 23 NA NA 40 (613) NA NA 57 RNV 92 (12/13) 60 (6/10)
Udelson et al. (47) 18 72 67 34 (610) NA 100 37 Echo 94 (16/17) 86 (25/29)
Maublant et al. (73) 25 92 62 52 (615) 60 NA 78 CV 100 (21/21) 67 (4/6)
Average 22 86 59 45 78 95 55
Weighted mean 81 (191/236) 60 (122/203)
Technetium-99m Sestamibi Scintigraphy With Addition of Nitrates
Maurea et al. (74) 8 NA NA NA NA 100 48 Echo 88 (22/25) 89 (24/27)
Bisi et al. (75) 19 89 57 35 (610) 84 100 24 Echo 91 (10/11) 88 (30/34)
Bisi et al. (76) 28 86 57 36 (610) 61 100 43 RNV 95 (18/19) 88 (22/25)
Average 18 87 57 36 70 100 37
Weighted mean 91 (50/55) 88 (76/86)
Abbreviations as in Table 1.
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Areas of ongoing research. It was recently suggested that
analysis of the response to high dose dobutamine in addition to
low dose dobutamine (82) or a combination of dobutamine
infusion with dipyridamole (0.28 mg/kg body weight over
4 min) (88) might further improve the results. To overcome the
limitations of transthoracic echocardiography, in terms of
patient-dependent image quality, several studies have demon-
strated the feasibility of transesophageal LDDE (23,79,80,
89,90).
Relative merits of the imaging techniques. The results of
the pooled analysis are summarized in Table 6. All techniques
have a high sensitivity for predicting recovery of rest regional
function. LDDE has a higher specificity than all other methods
(p , 0.01), and both Tl-201 approaches have significantly less
specificity than LDDE (p , 0.01), F-18 FDG PET (p , 0.01)
or Tc-99m MIBI SPECT (p , 0.05). As illustrated in Figure 1,
LDDE has the highest predictive accuracy.
Discussion
The current study revealed that sensitivity for predicting
improved regional contractile function after revascularization
is high for all techniques analyzed; however specificity varied
greatly for all techniques and was lowest for Tl-201 stress–
redistribution–reinjection and Tl-201 rest–redistribution. We
chose to present the data in terms of sensitivity and specificity
because the proportion of segments showing functional recov-
ery varied greatly from one study to another, and sensitivity
and specificity are less dependent than predictive values on the
prevalence of recovery or no recovery of rest function. There
Table 5. Sensitivity and Specificity for Low Dose Dobutamine Echocardiography for Detection of Improved Regional Contractile Function
After Revascularization
Study (ref no.)
No. of
Pts
Male
(%)
Mean Age
(yr)
Mean LVEF
(SD) (%)
Pts With
MVD (%)
Pts With
Prev MI
(%)
Segs With
Recovery
(%)
Technique Assessing
RWM After Revasc
Sens (%)
(no. of segs)
Spec (%)
(no. of segs)
Gerber et al. (7) 39 87 60 33 (610) 85 59 62 Echo 71 (17/24) 89 (13/15)
Charney et al. (50) 17 59 63 46 (69) 76 65 53 Echo 71 (22/31) 93 (25/27)
Arnese et al. (40) 38 68 59 31 (NA) 92 100 22 Echo 74 (28/38) 96 (127/132)
Perrone-Filardi
et al. (51)
34 NA NA 39 (614) NA NA 28 Echo 74 (31/42) 89 (94/106)
Afridi et al. (82) 20 85 60 NA 40 55 33 Echo 76 (29/38) 74 (56/76)
Vanoverschelde
et al. (42)
73 85 59 36 (612) 79 68 38 Echo/RNV 79 (211/267) 80 (340/425)
Qureshi et al. (52) 18 NA 61 NA 76 56 69 Echo 79 (58/73) 83 (30/36)
Marzullo et al. (46) 14 79 54 39 (67) 93 100 65 Echo 82 (40/49) 94 (24/26)
Bax et al. (34) 17 82 57 36 (611) 100 100 29 Echo 85 (23/27) 63 (41/65)
Senior et al. (83) 22 95 61 26 (68) 86 NA 70 Echo 87 (103/118) 82 (41/50)
Perrone-Filardi
et al. (84)
18 94 59 43 (612) 50 89 61 Echo 88 (42/48) 87 (27/31)
Alfieri et al. (49) 14 100 52 35 (68) NA NA 82 Echo 91 (85/93) 78 (25/32)
La Canna et al. (85) 33 97 56 33 (68) 94 70 65 Echo 92 (164/179) 75 (101/135)
Haque et al. (41) 26 81 55 43 (614) 56 88 77 Echo 94 (31/33) 80 (8/10)
Baer et al. (23) 42 90 59 40 (613) 74 100 62 Echo 96 (25/26) 69 (11/16)
DeFilippi et al. (86) 23 100 NA 38 (610) NA NA 61 Echo 97 (94/97) 75 (41/55)
Average 28 86 58 36 78 78 52
Weighted mean 84 (909/1086) 81 (963/1182)
Abbreviations as in Table 1.
Table 6. Sensitivity and Specificity for the Different Imaging Techniques (based on weighted mean
values from available studies)
No. of
Pts
Sens
(%) 95% CI 99% CI
Spec
(%) 95% CI 99% CI
Tc-99m MIBI 207 83 78–87 77–89 69 63–74 61–76
LDDE 448 84 82–86 81–87 81 79–84 79–84
Tl-201 reinjection 209 86 83–89 82–90 47 43–51 42–52
F-18 FDG PET 332 88 84–91 83–92 73 69–77 69–77
Tl-201 rest–redistribution 145 90 87–93 86–94 54 49–60 48–61
CI 5 confidence interval; F-18 FDG 5 fluorine-18 fluorodeoxyglucose; LDDE 5 low dose dobutamine echocardi-
ography; Tc-99m MIBI 5 technetium-99m sestamibi; Tl-201 5 thallium-201; other abbreviations as in Table 1.
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are data supporting the value of each diagnostic test discussed
here (with exception of Tc-99m MIBI) for predicting improve-
ment in global rest function; however, the number of available
studies remains too small to compare their respective accuracy.
On the basis of the search strategies that we used, we believe
that all available data as of March 1997 are included in the
present analysis. Given the relatively small sample size of the
individual studies and the lack of randomized data, it was not
possible to perform a formal meta-analysis that included the
assessment of the effect of variation in study validity and the
effect of variation in patient characteristics (91). However, by
restricting our analysis to patients with chronic LV dysfunc-
tion, a relatively homogenous study group was defined. More-
over, the study populations did not differ substantially (Tables
1 to 5). Still, some variation in the quality of the data is possible
despite our attempts to reduce it by setting narrow inclusion
criteria. It should be acknowledged that variations between the
studies may still occur from the use of different criteria for
defining a positive or negative test result; for instance, many
different viability criteria and analytical procedures have been
described for Tl-201 and F-18 FDG imaging.
In practice, the choice between imaging modalities also
depends on local availability and expertise, which is particu-
larly critical for the acquisition and interpretation of LDDE.
Of the nuclear techniques, it appears that the Tl-201 stress–
redistribution–reinjection approach is the least effective. Be-
cause most tests do not have equivalent performance charac-
teristics, complementary techniques could be combined to
obtain an optimal balance between sensitivity and specificity.
Strategies can be developed for a more cost-effective use of
tests in a sequential manner, as preliminary data suggest (92).
Limitations of the available data and new areas of re-
search. This analysis of the published data reveals some of the
weaknesses of the currently available evidence. The inclusion
criteria may vary considerably from one study to the other,
particularly with respect to the severity of baseline dysfunction.
Ideally, only patients with a global ejection fraction ,35%
should be studied because these patients are both likely to
benefit from and to have a greater risk during a revasculariza-
tion procedure. Most studies included only a limited number of
patients. Information about patients lost to follow-up is rarely
given, and partial data duplication seems likely in a few
reports. The majority of studies do not provide evidence of
vessel or graft patency; reocclusion may prohibit viable seg-
ments from recovering, thereby underestimating the true spec-
ificity of all techniques. The optimal moment for the assess-
ment of functional follow-up after revascularization is
uncertain. Currently, follow-up is frequently performed 3
months after revascularization. However, preliminary data (93)
have demonstrated that full recovery should not be expected to
occur before 6 or even 12 months after revascularization.
Importantly, global and regional function should be evalu-
ated by an independent technique. Studies of LDDE have
invariably used echocardiograms to evaluate the effect of
revascularization. The use of an internally consistent standard
may contribute in part to the excellent predictive value of this
technique. In addition, the acquisition and interpretation of
echocardiograms strongly depends on operator experience.
Although variability in interpretation of stress echocardio-
grams between institutions has been reported for the diagnosis
of CAD (94), no such data are available for the detection of
contractile reserve in dysfunctional areas (95).
Finally, it should be acknowledged that a prospective,
long-term evaluation of patients with severe dysfunction with
and without revascularization is still awaited. The presence of
viable myocardium may have implications and long-term ef-
fects on prognosis that are independent from the rest func-
tional state of the left ventricle (96–98). Therefore, additional
end points, such as the response during stress (99), exercise
capacity (100) and quality of life (101), should be prospectively
evaluated in a large patient cohort.
Conclusions. The current analysis of pooled data showed
that sensitivity for prediction of functional recovery after
revascularization is high for all techniques reviewed here.
Specificity is highest for LDDE and lowest for Tl-201 stress–
redistribution–reinjection and Tl-201 rest–redistribution.
Thus, the available evidence favors the use of LDDE as the
technique of first choice for prediction of regional functional
recovery in patients with chronic ischemic LV dysfunction for
whom revascularization is contemplated.
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